3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
10
INDUSTRY
3
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
2
Carcinoma
2
Adenocarcinoma
2
Sarcoma, Ewing
1
Gastrointestinal Stromal Tumors
1
Colonic Neoplasms
1
Interventions
Fluorouracil
20
Leucovorin
18
Oxaliplatin
11
Irinotecan
10
Capecitabine
6
Bevacizumab
5
Cetuximab
4
Levamisole
3
Celecoxib
3
cediranib
2
Watchful Waiting
2
Tegafur
2
Surveys and Questionnaires
2
Psychiatric Rehabilitation
2
Folfox protocol
2
Counseling
2
Cisplatin
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
regorafenib
1
pertuzumab
1
olaparib
1
mercaptoundecahydrododecaborate
1
gevokizumab
1
eniluracil
1
cemiplimab
1
brivanib
1
alpha-Tocopherol
1
Vitamin E
1
Uracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Colonic Neoplasms
×
regorafenib
×
Clear all
NCT02664077
2022-04-14
ARGO
NSABP Foundation Inc
Phase 3
Terminated
34 enrolled